Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.

Abstract

Treatment of Buruli ulcer, or Mycobacterium ulcerans disease, has shifted from surgical excision and skin grafting to antibiotic therapy usually with 8 weeks of daily rifampin (RIF) and streptomycin (STR). Although the results have been highly favorable, administration of STR requires intramuscular injection and carries the risk of side effects, such as hearing loss. Therefore, an all-oral, potentially less toxic, treatment regimen has been sought and encouraged by the World Health Organization. A combination of RIF plus clarithromycin (CLR) has been successful in patients first administered RIF+STR for 2 or 4 weeks. Based on evidence of efficacy of clofazimine (CFZ) in humans and mice with tuberculosis, we hypothesized that the combination of RIF+CFZ would be effective against M. ulcerans in the mouse footpad model of M. ulcerans disease because CFZ has similar MIC against M. tuberculosis and M. ulcerans. For comparison, mice were also treated with the gold standard of RIF+STR, the proposed RIF+CLR alternative regimen, or CFZ alone. Treatment was initiated after development of footpad swelling, when the bacterial burden was 4.64±0.14log10 CFU. At week 2 of treatment, the CFU counts had increased in untreated mice, remained essentially unchanged in mice treated with CFZ alone, decreased modestly with either RIF+CLR or RIF+CFZ, and decreased substantially with RIF+STR. At week 4, on the basis of footpad CFU counts, the combination regimens were ranked as follows: RIF+STR>RIF+CLR>RIF+CFZ. At weeks 6 and 8, none of the mice treated with these regimens had detectable CFU. Footpad swelling declined comparably with all of the combination regimens, as did the levels of detectable mycolactone A/B. In mice treated for only 6 weeks and followed up for 24 weeks, there were no relapses in RIF+STR treated mice, one (5%) relapse in RIF+CFZ-treated mice, but >50% in RIF+CLR treated mice. On the basis of these results, RIF+CFZ has potential as a continuation phase regimen for treatment of M. ulcerans disease.

• Authors: Paul J Converse, Sandeep Tyagi, Yalan Xing, Si-Yang Li, Yoshito Kishi, John Adamson, Eric L Nuermberger, Jacques H Grosset
• Journal: PLoS neglected tropical diseases (PLoS Negl Trop Dis) Vol. 9 Issue 6 Pg. e0003823 ( 2015) ISSN: 1935-2735 [Electronic] United States
• PMID: 26042792 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Macrolides
• mycolactone
• Clofazimine
• Clarithromycin
• Rifampin
• Streptomycin

Topics

• Animals
• Buruli Ulcer (drug therapy)
• Clarithromycin (pharmacology)
• Clofazimine (pharmacokinetics, pharmacology)
• Colony Count, Microbial
• Drug Evaluation, Preclinical
• Drug Therapy, Combination (methods)
• Foot (pathology)
• Macrolides (isolation & purification)
• Mice
• Microbial Sensitivity Tests
• Rifampin (pharmacology)
• Streptomycin (pharmacology)
• Survival Analysis
• Time Factors
• Treatment Outcome